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Key Message 
Yellow fever (YF), a mosquito-borne (Aedes aegypti) viral haemorrhagic fever, is one of the 
most lethal viral diseases. Despite the availability of vaccines, yellow fever virus (YFV) 
strikes an estimated 2, 00,000 persons world-wide each year and causes 30,000 deaths ap-
proximately (Schmaljohn, et al., 1996). There are no approved antiviral therapies for the treat-
ment of YF in human (Tomori, et al., 2004). YFV 17D strain R NA genome is of 10,862 nu-
cleotides, which encodes three structural proteins (C, PrM, and E) and seven nonstructural 
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5).  
Identification of different protein functions facilitates a mechanistic understanding of YFV     
infection and opens novel means for drug development. Functional assignment of complete 
YFV 17D proteome was done through support Vector machine (SVM) (Sahoo et al. 2008). 
The envelope (E) protein is the major structural protein of YFV17D and is understood to me-
diate several important virus functions such as host cell receptor-binding, membrane fusion 
activity and virion assembly (Heinz & Mandl, 1993). EMBOSS antigenic server (Dass et al., 
2008) and Pfam analysis (Eddy et al., 1997) deciphered E protein is the major antigen respon-
sible for induction of neutralizing antibodies and protective immunity in host. The YFV 17D 
E protein being non-homologous to human, we propose it as molecular target for structure 
based drug discovery (SBDD) against YFV 17D. 
3D structure of YFV 17D E protein was built based on crystal structure of Dengue virus 2 Ma-
jor envelope protein in MODELLER9V7 (Sahoo et al., 2009). Six selected lead molecules 
were docked to functionally important binding site of YFV 17D E protein using LigandFit 
(Sahoo et al., 2009) module of Discovery Studio 2.0. Heparin docked into the receptor bind-
ing site with a dock score of 42.11 and four hydrogen bonds (one each with SER 483, ALA 
441 and two with GLN 443). Hence, we propose to consider heparin as lead candidate for 
further ADME (Absorption, Disruption, Metabolism and Excretion) studies. 
Results and Discussion 
YFV proteome consists of 13 proteins. Structural and non-structural protein functions are metal -binding, lipid-
binding, copper-binding, calcium-binding, zinc-binding, magnesium-binding, DNA-binding, RNA-binding, trans-
membrane and outer membrane group of proteins. 
The YFV 17D E protein comprising of 493 amino acids and is among the family of metal-binding, outer membrane, 
the transmembrane protein, aptamer-binding protein, P-type ATPase - (P-ATPase) family, zinc-binding and coat pro-
tein. The functional families reveals its importance in receptor binding, hemagglutination of erythrocytes at acidic 
pH, induction of the protective immune response, and involvement in an intraendosomal acid-catalyzed fusion step 
necessary for infection. 
Twelve antigenic sites were predicted in YFV 17D E protein using EMBOSS antigenic server. Presence of more anti-
genic sites is expected to initiate strong immunogenic response in host. 
The E protein being a human non-homolog, plays an active role in viral infection and due to the presence of more an-
tigenic sites E protein was selected as a potent molecular target against YFV drug discovery. 
Pfam analysis revealed YFV 17D E protein having domains for induction of neutralizing antibodies and protective 
immunity. 
Three Dimensional structure of YFV 17 D E protein was built based on crystal structure of Dengue virus 2 Major en-
velope protein (PDB ID: 1P58) in MODELLER9V7. The model evaluation using PROCHECK revealed 97.7% resi-
dues are in favorable region (Fig.1). The model was visualized through RASMOL (Fig.2). The structure was energy 
minimized (-7.95 kcal/mol) using CHARMm. 
Twenty nine selected ligand molecules specific for envelope protein were downloaded and prepared using LigandFit 
(Lee et al 2004). Only six ligand molecules seemed to follow Lipinski’s rule of five. 
The six prepared ligand molecules were docked to functionally important binding site of YFV 17D E protein using 
LigandFit (Sahoo et al., 2009) module of Discovery Studio 2.0. Heparin docked into the receptor binding site with a 
dock score of 42.11 shown in table 1, and four hydrogen bonds (one each with SER 483, ALA 441 and two with GLN 
443) in sixth pose shown in Fig. 3A and 3B. The residues such as ALA441, PHE442, LUE487 and VAL491 are form-
ing hydrophobic pocket while GLN250, GLU251, ASN62 and ASN259 are forming hydrophilic surface around the 
active site. These residues were involved in hydrophobic and hydrophilic interaction respectively with the ligand 
molecule. 
The residues involved in hydrogen bond are GLY 433, ALA 441 and SER 488. Hydrophobic residues (ALA441,   
PHE442 and LEU 487) and hydrophilic residues (ASN62) of YFV 17D E protein involved in docking interaction 
with heparin are also part of an epitope identified using Jemboss. So, based on the results obtained through the dock-
ing studies we can conclude that heparin can be used as a lead molecule. Further ADME (Absorption, Disruption, 
Metabolism and Excretion) studies to confirm the activity of the molecule which needs to be tested for biological ac-
tivity before entering into human clinical trials.  
DOCKING RESULTS 
Number of binding sites 14 
Number of  poses found 10 
Clustering the final poses 6 
Best docking score 42.11 
Best Ligand Pose : energy -7.95 kcal/mol 
Number of Hydrogen bonds 4 
CONCLUSION 
The protein function family was identified common to YFV 17D proteome would facilitate 
mechanistic understanding of YFV infection and opens novel means for drug development.  
The YFV 17D E protein was important role in receptor binding, hemagglutination of eryth-
rocytes at acidic pH, induction of the protective immune response, and involvement in an 
intraendosomal acid-catalyzed fusion step necessary for infection. 
The predicted 3D model of YFV 17 D E protein is of good quality. Hence the functional     
domain of the protein could be used for structure based virtual screening in order to obtain 
more ligands. 
The lead candidate heparin blocks the functionally important site of YFV 17D E protein by 
forming hydrogen bonds, hydrophobic, hydrophilic and electrostatic interaction. Hence, the 
heparin would be considered as a good drug molecule. 
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Figure1: PROCHECK VALIDATION REPORT.   Figure 2: 3D STRUCTURE OF YFV 17D ENVELOPE PROTIEN  
Figure 3A: HEPARIN DOCKED WITH  
ENVELOPE PROTEIN OF YFV 17D     
FIGURE 3B: HYDROGEN BONDS BETWEEN  
THE TARGET PROTEIN AND THE LIGAND  
Material and Methods 
Whole proteome was retrieved from NCBI Ref seq FTP server 
Protein function family prediction using SVMProt 
Antigenic property prediction in Jemboss antigenic server 
BLASTP of YFV 17D E protein against Homo sapiens  
Building 3D model of YFV 17D E protein using MODELLER9v7 
Model validation using PROCHECK 
Protein – Ligand Docking using the LigandFit of Dis-
Proteomic analysis of YFV 17D E protein 
Ligand searching 
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